
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. has demonstrated a robust growth trajectory, as evidenced by a 2% quarter-over-quarter increase in Jornay PM prescriptions during both 2Q25 and 3Q25, along with a significant 24% year-over-year growth in total prescriptions from 1Q24 to 1Q25. The company has revised its 2025 guidance, reflecting a positive outlook with projected top-line expectations raised to $745 million to $760 million, while also forecasting an adjusted EBITDA growth to between $440 million and $455 million. Additionally, Jornay PM sales for 2Q25 reached $32.6 million, showing a 14% quarter-over-quarter increase and exceeding the growth rates in its prescriptions, further supporting a favorable financial outlook for the company.
Bears say
Collegium Pharmaceutical has experienced mixed performance in its pain portfolio, with prescriptions for Xtampza ER and Nucynta showing declines of 1% and 2%, respectively, which may reflect challenges in market acceptance. Additionally, concerns about the company's reliance on third-party suppliers for product quality and regulatory compliance could hinder commercialization efforts and profit margins. With impending potential losses of exclusivity for key products like Nucynta and Belbuca in 2027, the company faces significant risks that could adversely impact future cash flows and overall financial health.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares